-24.34% percent quarterly performance for AbCellera Biologics Inc (ABCL) is not indicative of the underlying story

AbCellera Biologics Inc (NASDAQ: ABCL) kicked off on Tuesday, down -2.70% from the previous trading day, before settling in for the closing price of $4.44. Over the past 52 weeks, ABCL has traded in a range of $3.87-$8.05.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Healthcare Sector giant saw their annual sales surged by 387.52% over the last five years. While this was happening, its average annual earnings per share was recorded 5.79%. With a float of $205.17 million, this company’s outstanding shares have now reached $290.82 million.

The firm has a total of 586 workers. Let’s measure their productivity.

AbCellera Biologics Inc (ABCL) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of AbCellera Biologics Inc is 29.92%, while institutional ownership is 38.38%. The most recent insider transaction that took place on May 26 ’23, was worth 997,728. In this transaction 10% Owner of this company bought 153,000 shares at a rate of $6.52, taking the stock ownership to the 56,012,493 shares. Before that another transaction happened on May 26 ’23, when Company’s Chief Financial Officer bought 14,500 for $6.85, making the entire transaction worth $99,325. This insider now owns 153,000 shares in total.

AbCellera Biologics Inc (ABCL) Earnings and Forecasts

In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$0.17 earnings per share (EPS), lower than consensus estimate (set at -$0.13) by -$0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 5.79% per share during the next fiscal year.

AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators

Take a look at AbCellera Biologics Inc’s (ABCL) current performance indicators. Last quarter, stock had a quick ratio of 7.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 33.26.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.47 in one year’s time.

Technical Analysis of AbCellera Biologics Inc (ABCL)

Analysing the last 5-days average volume posted by the [AbCellera Biologics Inc, ABCL], we can find that recorded value of 1.3 million was lower than the volume posted last year of 1.44 million. As of the previous 9 days, the stock’s Stochastic %D was 28.57%. Additionally, its Average True Range was 0.23.

During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 19.86%, which indicates a significant increase from 7.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.36% in the past 14 days, which was lower than the 55.55% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $4.96, while its 200-day Moving Average is $5.36. Now, the first resistance to watch is $4.42. This is followed by the second major resistance level at $4.51. The third major resistance level sits at $4.59. If the price goes on to break the first support level at $4.25, it is likely to go to the next support level at $4.17. Should the price break the second support level, the third support level stands at $4.08.

AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats

The company with the Market Capitalisation of 1.26 billion has total of 292,782K Shares Outstanding. Its annual sales at the moment are 38,030 K in contrast with the sum of -146,400 K annual income. Company’s last quarter sales were recorded 9,180 K and last quarter income was -47,150 K.